• Legend Biotech launched an underwritten public offering of USD 225 million of ADSs, each representing two ordinary shares.
• Deal includes a 30-day option for underwriters to buy up to 15% more ADSs at the offering price, less discounts.
• Morgan Stanley, Jefferies, Citigroup, Deutsche Bank Securities are joint bookrunners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606171629PRIMZONEFULLFEED9748834) on June 17, 2026, and is solely responsible for the information contained therein.